Lepticore in Metabolic Syndrome and Weight Loss

The Use of LeptiCore® in Reducing Fat Gain and Managing Weight Loss in Patients With Metabolic Syndrome

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01046968

Enrollment

Registered

2010-01-12

Start date

2009-08-31

Completion date

2009-11-30

Last updated

2010-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia, Hyperlipidemia, Obesity

Keywords

Obesity, metabolic syndrome, C-reactive protein, Leptin

Brief summary

Metabolic syndrome is directly related to obesity. This study investigated the use of a plant based formulation to improve on the condition of people with metabolic syndrome.

Detailed description

LeptiCore is a proprietary combination of various ingredients which have been shown to have properties which could be beneficial to weight loss in obese and overweight human subjects. This study evaluates the effect of Lepticore on bodyweight as well as parameters associated with obesity and metabolic syndrome. The study was an 8 week randomized, double-blind, placebo-controlled design involving 92 obese (mean BMI\>30kg/m2) participants (37 males; 55 females; ages 19-52; mean age = 30.7). The participants were randomly divided into three groups: placebo (n=30), LeptiCore formula A (low dose) (n=31) and LeptiCore formula B (high dose) (n=31). Capsules containing the placebo or active formulations were administered twice daily before meals with 300 ml of water. None of the participants followed any specific diet nor took any weight-reducing medications for the duration of the study. A total of 12 anthropomorphic and serological measurements were taken at the beginning of the study and after 2, 4, 6, and 8 weeks of treatment.

Interventions

DIETARY_SUPPLEMENTLepticore

300 mg twice daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

19 Years to 52 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI \>30 kg/m2 * Total cholesterol \>200 mg/dl * LDL cholesterol \>160 mg/dl * HDL cholesterol \<40 mg/dl; triglycerides \>150 mg/dl * Fasting blood glucose \>100 mg/dl * Blood pressure \>130/85 mmHg.

Exclusion criteria

* Morbid obesity (BMI \>40 kg/m2 ) * Diabetes mellitus requiring daily insulin management * Pregnancy/lactation * Active infection * Systemic disease such as HIV/AIDS, * Use of any cholesterol-lowering medications 30 days prior to study * Enrollment in another clinical study within the past 6 months.

Design outcomes

Primary

Measure	Time frame
Improvement of symptoms of metabolic syndrome	8 weeks

Secondary

Measure	Time frame
Change in weight	8 weeks

Countries

Cameroon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026